Abstract
Abstract
Background
As for any other nuclear medicine treatment, patients treated with [177Lu]Lu-DOTA-TATE should be given some radiation protection recommendations after being discharged to limit the dose received by family members and public. The restriction periods will depend on the remaining activity at the time of discharge, the washout rate and patients’ personal conditions. The activity in patients’ whole-body follows a bi-exponential behaviour. At the time of discharge only the first part of the time-activity curve is known. However, the second phase of the bi-exponential curve should be known to individualize the time of restrictions. The main purpose of this prospective study was to establish a simple method for calculating the restriction periods based on measurements taken before discharge.
Methods
The whole-body time-activity curve was calculated for 20 patients from dose-rate measurements performed during the first week post-administration. An effective decay time $$T_{{{\text{eff}}}}^{6,24}$$
T
eff
6
,
24
was calculated from a mono-exponential fit performed with the 6 h and 24 h measurements and compared with the effective decay time $$T_{{{\text{eff}}}}^{24,48,168}$$
T
eff
24
,
48
,
168
obtained from the mono-exponential fit performed with the 24 h, 48 h and 168 h measurements. The differences between them were calculated and the 95th percentile of these differences was used as a correction factor for $$T_{{{\text{eff}}}}^{6,24}$$
T
eff
6
,
24
. A modified effective decay $$T_{{{\text{eff}},{\text{ mod}}}}^{6,24}$$
T
eff
,
mod
6
,
24
was obtained by adding the correction factor to $$T_{{{\text{eff}}}}^{6,24}$$
T
eff
6
,
24
and the restriction periods for each patient was calculated. The whole body activity washout between the first and the fourth treatment cycles of 16 patients was also compared.
Results
The comparison of the whole-body activity curves between the first and the fourth cycle of the treatment for 16 patients would indicate that the recommendations on radiation protection determined from the first cycle could reasonably be used for the remaining cycles in most patients. The values of $$T_{{{\text{eff}}}}^{6,24}$$
T
eff
6
,
24
and $$T_{{{\text{eff}}}}^{24,48,168}$$
T
eff
24
,
48
,
168
obtained for the 20 patients were significantly different. The 95th percentile of the differences between $$T_{{{\text{eff}}}}^{6,24}$$
T
eff
6
,
24
and $$T_{{{\text{eff}}}}^{24,48,168}$$
T
eff
24
,
48
,
168
was 46 h, which is thus the time to be added to $$T_{{{\text{eff}}}}^{6,24}$$
T
eff
6
,
24
so as to determine the restriction periods.
Conclusions
The proposed method makes it possible to calculate the restriction periods for patients treated with [177Lu]Lu-DOTA-TATE before they leave the hospital in a conservative and individualized way.
Publisher
Springer Science and Business Media LLC
Subject
Radiology, Nuclear Medicine and imaging,Instrumentation,Biomedical Engineering,Radiation
Reference27 articles.
1. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754–62.
2. BNM-LNHB/CEA-Table de radionucléides-177Lu [Internet]. Laboratoire National Henri Becquerel. Available from: http://www.nucleide.org/DDEP_WG/Nuclides/Lu-177_tables.pdf.
3. ICRP Publication 94. Release of patients after therapy with unsealed radionuclides. Stockholm: Elsevier; 2004.
4. ICRP Publication 103. The 2007 recommendations of the International Commission on Radiological Protection. Oxford: Elsevier; 2007.
5. Levart D, Kalogianni E, Corcoran B, Mulholland N, Vivian G. Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours. EJNMMI Phys. 2019;6:7.